Want to see CTNM full AI Analyst Report?
CTNM Stock Chart & Stats
$17.02
$0.22(1.56%)
At close: 4:00 PM EDT
$17.02
$0.22(1.56%)
Day’s Range― - ―
52-Week Range$8.60 - $17.79
Previous CloseN/A
Volume15.74K
Average Volume (3M)475.11K
Market Cap
$628.27M
Enterprise Value$384.12
Total Cash (Recent Filing)$236.55M
Total Debt (Recent Filing)$6.57M
Price to Earnings (P/E)―
Beta0.32
Next Earnings
Nov 11, 2026EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.73
Shares Outstanding32,958,633
10 Day Avg. Volume382,184
30 Day Avg. Volume475,112
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)1.21
Price to Sales (P/S)0.00
P/FCF Ratio-5.70
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$23.80Price Target Upside39.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.56
Revenue Forecast (FY)$8.26M
Bulls Say, Bears Say
Bulls Say
Low Leverage And Solid Equity BaseLow debt relative to equity gives Contineum financial flexibility to fund research and operations without heavy interest or refinancing pressure. The positive equity base provides a stronger foundation for advancing programs than a highly leveraged balance sheet.
Lead Program Has Encouraging Clinical SignalsEncouraging early safety and efficacy findings for PIPE-791 improve the probability that the lead asset can advance into larger studies. Clinical validation could support development in chronic pain and idiopathic pulmonary fibrosis, broadening its strategic potential.
Capital Runway And Focused Development StrategyA runway through mid-2029 allows continued clinical execution while reducing near-term financing dependence. Prioritizing PIPE-791 and deferring CTX-343 also concentrates resources on the most advanced opportunity, supporting capital discipline.
Bears Say
No Recurring Product RevenueThe absence of recurring product revenue leaves Contineum dependent on financing, partnerships or future approvals to fund operations. Persistent losses also show that the business model has not yet reached commercial validation, making outcomes highly dependent on pipeline success.
Escalating Cash BurnNegative and worsening cash generation increases the amount of capital required before commercialization. Even with a strong balance sheet and stated runway, sustained R&D spending may require future equity, debt or partnership funding that could dilute flexibility.
Pipeline Concentration And Funding DependenceDependence on PIPE-791 and external funding or partnership support for other programs increases execution and concentration risk. Delaying CTX-343 limits pipeline breadth, while partner reliance may reduce control over timelines, investment and future economics.
Contineum Therapeutics, Inc. Class A News
CTNM FAQ
What was Contineum Therapeutics, Inc. Class A’s price range in the past 12 months?
Contineum Therapeutics, Inc. Class A lowest stock price was $8.60 and its highest was $17.79 in the past 12 months.
What is Contineum Therapeutics, Inc. Class A’s market cap?
Contineum Therapeutics, Inc. Class A’s market cap is $628.27M.
When is Contineum Therapeutics, Inc. Class A’s upcoming earnings report date?
Contineum Therapeutics, Inc. Class A’s upcoming earnings report date is Nov 11, 2026 which is in 65 days.
How were Contineum Therapeutics, Inc. Class A’s earnings last quarter?
Contineum Therapeutics, Inc. Class A released its earnings results on Jul 30, 2026. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.449 by $0.049.
Is Contineum Therapeutics, Inc. Class A overvalued?
According to Wall Street analysts Contineum Therapeutics, Inc. Class A’s price is currently Undervalued.
Does Contineum Therapeutics, Inc. Class A pay dividends?
Contineum Therapeutics, Inc. Class A does not currently pay dividends.
What is Contineum Therapeutics, Inc. Class A’s EPS estimate?
Contineum Therapeutics, Inc. Class A’s EPS estimate is -0.45.
How many shares outstanding does Contineum Therapeutics, Inc. Class A have?
Contineum Therapeutics, Inc. Class A has 32,958,633 shares outstanding.
What happened to Contineum Therapeutics, Inc. Class A’s price movement after its last earnings report?
Contineum Therapeutics, Inc. Class A reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.449. Following the earnings report the stock price went down -1.651%.
Which hedge fund is a major shareholder of Contineum Therapeutics, Inc. Class A?
Currently, no hedge funds are holding shares in CTNM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Contineum Therapeutics, Inc. Class A Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.80 (39.84% Upside)
$23.80 (39.84% Upside)
Blogger Sentiment
Bullish
CTNM Sentiment 100%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 2.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 8.6%
Last 30 Days ▼ 8.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
51.95%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
36.90%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Contineum Therapeutics, Inc. Class A
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
CTNM Stock 12 Month Forecast
Average Price Target
$23.80
▲(39.84% Upside)
Technical Analysis
Tvardi Therapeutics
―
Capricor Therapeutics
―
Alpha Tau
―
Immuneering
―
enGene Holdings
―
Ownership Overview
0.52% Insiders
8.92% Mutual Funds
42.69% Other Institutional Investors
37.93% Public Companies and
Individual Investors